$192 B

MRK Mkt cap, 18-Oct-2018

$20.5 B

Merck Revenue Q2, 2018
Merck Net income (Q2, 2018)2.5 B
Merck Cash, 30-Jun-20185.3 B
Merck EV206.7 B

Merck Revenue Breakdown

Embed Graph

Merck revenue breakdown by business segment: 88.3% from Pharmaceutical, 8.7% from Animal Health and 3.0% from Other

Merck Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

44.0b42.2b39.5b39.8b40.1b

Revenue growth, %

(4%)(6%)1%

Cost of goods sold

16.0b15.2b14.4b13.9b

Gross profit

28.1b27.1b25.1b25.9b

Gross profit Margin, %

64%64%63%65%

R&D expense

10.2b

Operating expense total

10.2b

Pre tax profit

5.5b17.3b5.4b4.7b6.5b

Net Income

4.5b11.9b4.5b3.9b2.4b

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

9.3b9.8b10.5b9.4b9.9b10.0b20.5b

R&D expense

1.7b2.2b1.7b1.8b1.7b3.2b5.5b

Operating expense total

1.7b2.2b1.7b1.8b1.7b3.2b5.5b

Pre tax profit

1.6b1.5b2.9b2.0b2.4b1.3b3.4b

Net Income

1.1b1.2b2.2b1.6b2.0b741.0m2.5b

Merck Balance Sheet

Annual

usdY, 2009Y, 2010Y, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

9.3b10.9b13.5b13.5b15.6b7.4b8.5b6.5b6.1b

Accounts Receivable

7.2b6.6b6.5b7.0b6.9b

Inventories

6.2b5.6b4.7b4.9b5.1b

Current Assets

35.7b33.2b29.8b30.6b24.8b

PP&E

12.0b12.4b

Goodwill

12.3b13.0b17.7b18.2b18.3b

Total Assets

105.6b98.3b101.8b95.4b87.9b

Accounts Payable

2.3b2.6b2.5b2.8b3.1b

Dividends Payable

1.3b1.3b1.3b1.3b1.3b

Short-term debt

Current Liabilities

17.9b18.8b19.2b17.2b18.6b

Long-term debt

20.5b18.7b23.9b24.3b21.4b

Total Debt

20.5b18.7b23.9b24.3b21.4b

Retained Earnings

39.3b46.0b45.3b44.1b41.4b

Total Equity

52.3b48.8b44.8b40.3b34.6b

Debt to Equity Ratio

0.4 x0.4 x0.5 x0.6 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x0.3 x

Financial Leverage

2 x2 x2.3 x2.4 x2.5 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

14.1b15.8b9.7b11.4b8.0b6.9b7.5b9.7b6.6b7.9b11.7b7.8b4.5b5.3b

Accounts Receivable

7.6b7.2b7.0b6.5b6.7b6.5b6.4b6.9b6.9b7.4b7.1b7.4b7.2b7.3b

Inventories

6.7b6.4b6.1b5.8b5.5b5.3b5.1b5.1b5.2b5.2b5.1b5.4b5.4b5.2b

Current Assets

37.8b41.2b33.6b34.7b32.9b28.3b28.6b28.8b27.9b29.4b31.5b28.2b24.1b24.1b

Goodwill

12.1b12.1b11.8b13.2b17.7b17.7b17.8b17.8b17.8b18.3b18.4b18.4b18.3b18.3b

Total Assets

106.0b108.0b97.9b102.0b108.0b103.0b101.0b98.8b96.5b98.3b96.6b92.8b86.0b85.0b

Accounts Payable

2.5b2.4b2.3b2.3b2.1b2.3b2.0b2.2b2.5b2.5b2.5b2.9b3.2b3.0b

Dividends Payable

1.3b1.3b1.3b1.3b1.3b1.3b1.3b1.3b1.3b1.3b1.3b1.3b1.3b1.3b

Current Liabilities

18.2b22.5b17.9b25.9b20.4b17.5b17.6b17.6b14.9b15.6b19.8b18.8b17.0b18.1b

Long-term debt

22.6b19.6b18.6b18.6b25.5b24.1b24.1b23.7b23.6b23.7b23.4b21.7b21.5b20.0b

Total Debt

22.6b19.6b18.6b18.6b25.5b24.1b24.1b23.7b23.6b23.7b23.4b21.7b21.5b20.0b

Retained Earnings

39.8b39.7b40.4b40.0b45.7b45.1b45.7b45.2b45.1b46.0b44.4b45.0b41.1b41.5b

Total Equity

50.0b52.6b48.5b45.4b47.9b46.6b45.7b43.9b43.4b44.0b40.1b39.7b33.9b32.8b

Financial Leverage

2.1 x2.1 x2 x2.2 x2.3 x2.2 x2.2 x2.2 x2.2 x2.2 x2.4 x2.3 x2.5 x2.6 x

Merck Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

4.5b11.9b4.5b3.9b2.4b

Depreciation and Amortization

4.6b

Accounts Receivable

436.0m(554.0m)(480.0m)(619.0m)297.0m

Inventories

(365.0m)79.0m805.0m206.0m(145.0m)

Accounts Payable

522.0m593.0m(37.0m)278.0m254.0m

Cash From Operating Activities

11.7b7.9b12.4b10.4b6.4b

Cash From Investing Activities

(3.1b)(374.0m)(4.8b)(3.2b)2.7b

Short-term Borrowings

(159.0m)(460.0m)(1.5b)(26.0m)

Cash From Financing Activities

(6.0b)(15.1b)(5.3b)(9.0b)(10.0b)

Free Cash Flow

13.2b9.2b13.7b12.0b4.6b

Quarterly

USDQ1, 2018Q2, 2018

Net Income

741.0m2.5b

Depreciation and Amortization

1.1b2.4b

Cash From Operating Activities

1.2b4.5b

Cash From Investing Activities

(197.0m)476.0m

Short-term Borrowings

(1.0m)2.1b

Cash From Financing Activities

(2.7b)(5.7b)

Free Cash Flow

705.0m3.5b

Merck Ratios

USDY, 2018

EV/CFO

45.6 x

EV/FCF

59 x

Financial Leverage

2.6 x
Report incorrect company information

Merck Operating Metrics

FY, 2015FY, 2016FY, 2017May, 2018

Drugs Approved by FDA

1

Phase III Trials Products

24 20

Products

30

Projects in R&D Pipeline

41 10
Report incorrect company information